Source: International Congress 2014 – ILDs 5
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Grah, C. Thieme, R. Seiberth, J. Arne, A. McCutcheon, S. Schreiber, J. Müller-Quernheim (Berlin, Kiel, Freiburg, Germany). Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis. Eur Respir J 2014; 44: Suppl. 58, 3765

Member's Comments

No comment yet.

Related content which might interest you: Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Successful treatment of alveolar proteinosis by inhaled GM-CSF and intravenous rituximab Source: International Congress 2014 – ILDs 5 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Atypical variants of clinical course of sarcoidosis Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Cognitive failure in sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014